Journal of Drug Metabolism & Toxicology

Journal of Drug Metabolism & Toxicology
Open Access

ISSN: 2157-7609

+44-77-2385-9429

SIEROLOGICAL IMPROVEMENT ON VACCINE ASSESSMENT TO A BETTER EFFICACY ON SARS-COV2 VARINATS


International Conference on Drug Discovery and Development - March 03-04, 2022 | Webinar

March 03-04, 2022 | Webinar

Antonio Steardo

Rome ??la Sapineza? University School of Medicine, ITALY

Scientific Tracks Abstracts: J Drug Metab Toxicol

Abstract :

Since Edward Jenner discovered in 1796, the first vaccine against smallpox, this therapeutic tool made the difference to fight epidemics. Even in this last case, vaccination on population decreased mortality and morbidity during SarS-CoV2 pandemic. The vaccine creates immunotrophycal barriers. It is thanks to the deployment of the pathogen in different phases of entry and replication on pulmonary and mucosal tissues. The last scientific evidence on the Covid-19 vaccine aims to assess efficacy by clinical trial phase 3 on immune correlates analysis of the vaccine mRNA-1237. Administering two doses, the second dose after four weeks, the vaccine efficacy has been tested on vaccine recipients with 50% neutralization titers 10,100,100. It has esteemed vaccines efficacies of 78% (95% confidence interval, 54 to 89%), 91% (87 to 94%), and 96% (94% to 98%) respectively. These results confirm the efficacy of a mRNA-1273 vaccine rather than other vaccines. Further steps should have been done to assess efficacy on variants by VN-Ab antigen as laboratory measurement. It can predict outcomes on large scale studies for SarS-CoV2 vaccine efficacy. This test can predict SarS-CoV2 infection resistance for variants, e.g., on the Omicron variant. By focusing on early serological laboratory, measurements can assess non-protective levels in some vaccines for five up to six months, assessing the efficacy on extended memory immune response. This test is a different way to assess vaccines rather than evaluate morbidity and mortality in large scale trial assessment. It would make it possible to assess the efficacy like the Omicron variant case.

Biography :

Dr. Rabbany completed her Bachelors in Psychology at the University of California, Berkeley at the age of 20. She received her medical training at the Sackler School of Medicine. She is currently a Psychiatry Resident Physician at Arrowhead Regional Medical Center and a Research Investigator at Cornell School of Medicine as well as at Columbia University. She is amongst the 2021 awardees of the SCPS/ PER Excellence in Psychiatric Education Award.

Top